Exchange & Returns Information
Review Details
(2)
| Generic For | SPRYCEL |
|---|---|
| Active Ingredient | DASATINIB |
| Strength | 20MG |
| Manufacturer | NATCO PHARMA LTD |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 2 BOXES - 120 TABLETS | $ 0.83 | $ 100.00 |
$ 85.00
Apply ZARVY26 (-15%)
You save $ 15.00
|
||
| 3 BOXES - 180 TABLETS | $ 0.86 | $ 154.00 |
$ 130.90
Apply ZARVY26 (-15%)
You save $ 23.10
|
||
| ★ Best Value 4 BOXES - 240 TABLETS | $ 0.84 | $ 202.00 |
$ 171.70
Apply ZARVY26 (-15%)
You save $ 30.30
|
Reference information will be available soon.
Dasanat 20 is a generic formulation of dasatinib, a second-generation tyrosine kinase inhibitor (TKI) with high potency against BCR-ABL and SRC-family kinases. It is indicated primarily for hematologic malignancies harboring the Philadelphia chromosome, offering a targeted mechanism to inhibit abnormal cell proliferation. Dasanat 20 exhibits rapid cytogenetic response and is frequently selected for patients resistant or intolerant to imatinib. It also plays a crucial bridging role prior to stem cell transplant in advanced leukemias.
- AntiCancer Drugs > Philadelphia chromosome-positive leukemias (CML, Ph+ ALL) Dasanat 20 is used in adult and pediatric patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is effective in both frontline and salvage settings, particularly when imatinib fails. Additionally, it is employed in blast crisis phases of CML and as a central nervous system–penetrating agent in advanced ALL.
- Potent inhibition of BCR-ABL1 kinase (including mutant forms resistant to imatinib) - SRC-family kinase blockade (e.g., LYN, FYN), suppressing leukemic signaling - Ability to penetrate sanctuary sites such as the CNS - Rapid induction of hematologic and cytogenetic remission
1. Adult Dosage – Leukemia - Chronic Phase CML: 100 mg orally once daily - Accelerated Phase CML / Myeloid or Lymphoid Blast Phase CML / Ph+ ALL: 140 mg orally once daily Treatment should be continued until disease progression or unacceptable toxicity. Therapeutic goals include complete hematologic response (CHR), cytogenetic remission, and long-term disease control. Dose adjustments may be required for hematologic toxicity or fluid retention. 2. Pediatric Dosage – Leukemia - Body weight 10 to <20 kg: 40 mg orally once daily - Body weight 20 to <30 kg: 60 mg orally once daily - Body weight 30 to <45 kg: 70 mg orally once daily - Body weight ≥45 kg: 100 mg orally once daily In pediatric Ph+ ALL, dasatinib should be initiated no later than Day 15 of induction chemotherapy. Treatment is continued for up to 2 years unless relapse or toxicity occurs. Weight-based reassessment is recommended every 3 months. Tablets are not suitable for children under 10 kg.
Store in a tightly closed container at temperatures below 25°C (77°F). Protect from moisture and direct sunlight. Keep out of reach of children. Do not crush or split tablets due to potential occupational exposure risk.
- Common: fatigue, diarrhea, headache, rash, nausea - Hematologic: neutropenia, thrombocytopenia, anemia - Serious: pleural effusion, QT prolongation, pulmonary arterial hypertension - Other: myelosuppression, fluid retention, bleeding tendency
My oncologist started me on the 20mg dose of Dasanat. This pharmacy provides a reliable and professional service for this vital medication.
Managing leukemia is my top priority, and having a pharmacy I can depend on is a huge relief. Their service has been excellent.
No combo deals available at the moment.
